Close Menu

SAN FRANCISCO (GenomeWeb) – The Lung Cancer Master Protocol (Lung-MAP) umbrella trial has expanded to enable all patients with advanced non-small cell lung cancer to enroll from its previous focus on advanced squamous cell lung cancer only.

In addition, researchers will begin implementing liquid biopsy as a screening protocol, initially in a pilot study to ensure that the results are comparable to tissue-based testing.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.